Lactobacilli are prevalent members of the microbiota in the intestinal and reproductive tracts of humans and other species. They are commonly used in probiotics due to their beneficial effects on human health, including their association with protection from numerous chronic diseases. In addition, these microbes are often prescribed to maintain their presence in the host during antibiotic therapy, as well as to treat diarrhea caused by antibiotics. Despite many studies examining the beneficial effects of lactobacilli, less is known about how they survive during antibiotic treatment, and in particular, whether they exhibit heteroresistance, a phenotype in which only a minor subpopulation of resistant cells coexists with a majority susceptible population. Here, we tested representative Lactobacillus species for heteroresistance to a broad panel of relevant antibiotics. The results demonstrate that Lactobacillus strains, including those isolated from human feces, can exhibit heteroresistance to relevant antibiotics from distinct classes, and are often heteroresistant to fluoroquinolones. In particular, heteroresistance to fluoroquinolones was even observed in Lactobacillus rhamnosus GG, a widely used probiotic. These findings significantly impact our understanding of how lactobacilli, including strains isolated from human samples, can survive antibiotic treatment, and how individual probiotic strains may be selected for use during antibiotic therapy to promote their survival and maximize their benefits. IMPORTANCE: Commensal bacteria, such as Lactobacillus species, are widely used for their beneficial effects on gastrointestinal health and their potential to help restore the gut microbial community after antibiotic use. However, the antibiotic resistance profiles of these beneficial bacteria have received limited attention despite their relevance to probiotic use. Heteroresistance is a phenomenon in which a small subpopulation of resistant bacteria within an otherwise susceptible community survives antibiotic exposure, but it is often undetected, underappreciated, and has largely not been investigated among commensal bacteria. Our study provides a characterization of heteroresistance across distinct Lactobacillus species and a panel of antibiotics, revealing that heteroresistance is far more widespread than previously appreciated, especially to fluoroquinolones. These findings suggest probiotic strains could be selected that would survive concurrent antibiotic therapy and thus highlight that more comprehensive resistance profiling of probiotic bacteria may yield benefits to patients.